Physician profile
Robert A Haggard
NPI 1477513711
$365.17
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $104.78 | 2019 | |
| Glaxosmithkline, LLC. | $72.11 | 2019 | |
| Amarin Pharma, INC. | $33.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $29.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.27 | 2019 | |
| Daiichi Sankyo INC. | $25.39 | 2019 | |
| Pfizer INC. | $23.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.03 | 2019 | |
| Merck Sharp & Dohme LLC | $11.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.25 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Haggard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.